Activities of Targeted Alpha Therapy at Osaka University

Abstract

Targeted Alpha Therapy （TAT） is one of the drug therapies to kill cancer cells by delivering high-energy alpha emitting nuclides to them. We have been developing and evaluating a short-lived alpha emitting nuclides, astatine-211 （²¹¹At）, and drug candidate compounds labeled with it. In this article, we review the results of our cross-departmental collaborative research and development, mainly conducted at Osaka University, including the production/purification of ²¹¹At, synthesis of targeting molecules, and the path to clinical trials.